A 59-year-old man with a 2-year history of sudden onset of hearing loss in the left ear was treated with tissue plasminogen activator (tPA) for myocardial infarction. The patient had 50 dB of hearing recovery after the full dose (100 mg of tPA followed by 3 mg/d of tPA for 2 weeks).
BanyaiLVaradiAPatthyL. Common evolutionary origin of the fibrin-binding structures of fibronectin and tissue-type plasminogen activator. FEBS Lett1983; 163: 37–41.
2.
RadcliffeRHeinzeT. Stimulation of tissue plasminogen activator by denatured proteins and fibrin clots: A possible additional role for plasminogen activator?. Arch Biochem Biophys1981; 211: 750–61.
3.
ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet1992; 339: 753–70.
4.
LagaresAGomezPALobatoRDAlenJFCampolloJBenito-LeonJ. Cerebral aneurysm rupture after r-TPA thrombolysis for acute myocardial infarction. Surg Neurol1999; 52: 623–6.
5.
SloanMAPriceTRPetitoCK. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: The Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience. Neurology1995; 45: 649–58.
6.
HagenR. Fibrinolytic therapy in sudden deafness with recombinant tissue-type plasminogen activator. Hemorheologic and therapeutic effects [in German]. Laryngorhinootologie1991; 70: 353–8.
KuboTMatsunagaTAsaiH. Efficacy of defibrinogenation and steroid therapies on sudden deafness. Arch Otolaryngol Head Neck Surg1988; 114: 649–52.
9.
WeinaugP. Treatment of acute inner ear diseases (sudden deafness and vestibular disorder) with meclofenoxate and acetylsalicylic acid [in German]. HNO1988; 36: 226–9.
10.
SloanMAPriceTRTerrinML. Ischemic cerebral infarction after rt-PA and heparin therapy for acute myocardial infarction. The TIMI-II pilot and randomized clinical trial combined experience. Stroke1997; 28: 1107–14.
11.
RanhkoTKottiV. Comparison of carbogen inhalation and intravenous heparin infusion therapies in idiopathic sudden sensorineural hearing loss. Acta OtolaryngolSuppl (Stockh) 1997(suppl 529): 86–7.
12.
KitamuraKDoiKTakedaNMishiroYOkusaMKuboT. Statistical analysis of recovery from sudden deafness among treatment groups [in Japanese]. Nippon Jibiinkoka Gakkai Kaiho1996; 99: 1676–83.
13.
ShiraishiTKuboTOkumuraS. Hearing recovery in sudden deafness patients using a modified defibrinogenation therapy. Acta OtolaryngolSuppl (Stockh) 1993(suppl 501): 46–50.
14.
ShiraishiTKuboTMatsunagaT. Chronological study of recovery of sudden deafness treated with defibrinogenation and steroid therapies. Acta Otolaryngol (Stockh)1991; 111: 867–71.
15.
NakashimaTKunoKYanagitaN. Evaluation of prostaglandin El therapy for sudden deafness. Laryngoscope1989; 99: 542–6.
16.
LaurikainenEAantaaEKallinenJ. Electronystagmographic findings and recovery of cochlear and vestibular function in patients suffering from sudden deafness with a special reference to the effect of anticoagulation. Audiology1989; 28: 262–7.
